Profilo società

Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows:
- pharmaceutical products (70.6%): prescription drugs in the areas of specialty medicine (59.3% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (40.7%; mainly for the treatment of diabetes and cardiovascular diseases);
- human vaccines (17.4%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas;
- consumer health products (12%).
At the end of 2023, the group had 54 production sites throughout the world.
Net sales are distributed geographically as follows: France (5.5%), Europe (18.6%), the United States (43%), North America (1.6%) and other (31.3%).


Fonte: Cofisem - Ultimo aggiornamento: 2024-03-31

Dirigenti principali
Chief Executive Officer Paul Hudson
Chief Financial Officer Francois-Xavier Roger
Director Research & Development Houman Ashrafian
Chief Human Resources Officer Natalie Bickford
General Counsel Roy Papatheodorou
Chief Investor Relations Officer Eva Schaefer-Jansen


Fonte: Cofisem - Ultimo aggiornamento: 2024-03-31

Dati principali
Millenium 2023 2022 2021 2020 2019
Net sales 43.070 42.997 37.761 36.041 36.126
Income from ordinary activities 46.444 45.389 39.175 37.369 37.631
Operating income 7.875 10.656 8.126 14.141 3.125
Cost of financial indebtedness net 22 124 259 225 172
Equity-accounted companies contribution to income -115 68 39 359 255
Net profit from discontinued activities 0 -101
Net income 5.436 8.484 6.279 12.350 2.837
Net income (Group share) 5.400 8.371 6.223 12.314 2.806
Fiscal year end 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Length of fiscal year (month) 12 12 12 12 12
Currency & Unit EUR - millions EUR - millions EUR - millions EUR - millions EUR - millions
Account Standards IFRS IFRS IFRS IFRS IFRS

Fonte: Cofisem - Ultimo aggiornamento: 2024-03-31

Informazioni sull'azionariato
Treasury stock 1,28 %
BlackRock, Inc. 6,85 %
Free float 79,96 %
L'Oréal 9,35 %
Employees 2,56 %


Fonte: Cofisem - Ultimo aggiornamento: 2024-03-31

Per supporto nell'aggiornamento del company profile: MyQuestion.Italy@euronext.com.

Quotazioni, Book, Dividendi, Documenti Societari, Corporate Governance, Internal Dealing di Sanofi


Borsa Italiana non ha responsabilità per il contenuto del sito a cui sta per accedere e non ha responsabilità per le informazioni contenute.

Accedendo a questo link, Borsa Italiana non intende sollecitare acquisti o offerte in alcun paese da parte di nessuno.


Sarai automaticamente diretto al link in cinque secondi.